Lv5
1520 积分 2025-02-25 加入
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial
3个月前
已完结
Efficacy and Safety of Firsekibart in Gout Patients with Different Estimated Glomerular Filtration Rates
3个月前
已关闭
Firsekibart as a Prophylactic Treatment for Acute Gout Flare in Participants Initiating Urate‐Lowering Therapy: A Phase 2, Randomized, Open‐Label, Multicenter, Active‐Controlled Trial
3个月前
已完结
Acute gout attack in a peritoneal dialysis patient treated with Firsekibart: a case report
3个月前
已完结
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial
3个月前
已完结
Efficacy of subcutaneous tocilizumab in a patient with severe gout refractory to anakinra
11个月前
已完结
Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority Trial
1年前
已完结
PPARGC1B: insight into the expression of the gouty inflammation phenotype
1年前
已完结
Genetic variants of PPAR-gamma coactivator 1B augment NLRP3-mediated inflammation in gouty arthritis
1年前
已完结
Developing an interpretable machine learning model for diagnosing gout using clinical and ultrasound features
1年前
已完结
皖公网安备34019202002308
